Related Experiment Video
Updated: Jun 2, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Methods to predict and lower the risk of prostate cancer
Barbara Ercole1, Dipen J Parekh
1Department of Urology, University of Texas Health Science Center, San Antonio, USA.
Abstract:
Chemoprevention for prostate cancer (PCa) continues to generate interest from both physicians and the patient population. The goal of chemoprevention is to stop the malignant transformation of prostate cells into cancer. Multiple studies on different substances ranging from supplements to medical therapy have been undertaken. Thus far, only the studies on 5 alpha-reductase inhibitors (the Prostate Cancer Prevention Trial [PCPT] and Reduction by Dutasteride of Prostate Cancer Events [REDUCE] trial) have demonstrated a reduction in the risk of PCa, while results from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) concluded no decreased risk for PCa with selenium or vitamin E.
Insights
Chemoprevention aims to prevent prostate cancer (PCa). 5 alpha-reductase inhibitors show risk reduction, but selenium and vitamin E do not decrease PCa risk.
Area of Science:
- Oncology
- Preventive Medicine
- Urology
Background:
- Prostate cancer (PCa) chemoprevention is of significant interest to clinicians and patients.
- The primary objective of chemoprevention is to inhibit the malignant transformation of prostate cells.
Purpose of the Study:
- To review the efficacy of various chemopreventive agents for prostate cancer.
- To summarize findings from key clinical trials investigating PCa risk reduction.
Main Methods:
- Review of major clinical trials, including the Prostate Cancer Prevention Trial (PCPT) and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial.
- Analysis of results from the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Main Results:
- 5 alpha-reductase inhibitors demonstrated a reduction in prostate cancer risk in the PCPT and REDUCE trials.
- The SELECT trial concluded that selenium and vitamin E do not decrease the risk of prostate cancer.
Conclusions:
- 5 alpha-reductase inhibitors are effective chemopreventive agents for prostate cancer.
- Selenium and vitamin E supplementation do not offer a protective effect against prostate cancer.
More Related Videos
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Related Concept Videos
Cancer Prevention
Some...
Cancer Prevention
Some...
Coronary Artery Disease IV: Preventive Measures
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Preventive Healthcare Services
Atherosclerosis III: Management